Analysts Set Expectations for PLX FY2028 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Equities research analysts at Zacks Research issued their FY2028 EPS estimates for shares of Protalix BioTherapeutics in a research note issued on Thursday, May 14th. Zacks Research analyst J. Vandermosten anticipates that the company will earn $0.01 per share for the year. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share.

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Protalix BioTherapeutics in a report on Thursday, March 19th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $12.00.

Protalix BioTherapeutics Stock Down 0.5%

Shares of PLX opened at $1.90 on Monday. Protalix BioTherapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $3.19. The firm’s 50 day moving average price is $2.24 and its 200 day moving average price is $2.21. The company has a market cap of $153.09 million, a P/E ratio of -14.62 and a beta of -0.01.

Institutional Trading of Protalix BioTherapeutics

Large investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in shares of Protalix BioTherapeutics by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 830,054 shares of the company’s stock valued at $1,494,000 after purchasing an additional 10,277 shares in the last quarter. State Street Corp increased its holdings in shares of Protalix BioTherapeutics by 17.4% in the 4th quarter. State Street Corp now owns 585,261 shares of the company’s stock valued at $1,053,000 after purchasing an additional 86,714 shares in the last quarter. Stratos Wealth Partners LTD. increased its holdings in shares of Protalix BioTherapeutics by 42.9% in the 3rd quarter. Stratos Wealth Partners LTD. now owns 500,000 shares of the company’s stock valued at $1,110,000 after purchasing an additional 150,000 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Protalix BioTherapeutics by 932.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 296,843 shares of the company’s stock valued at $644,000 after purchasing an additional 268,099 shares in the last quarter. Finally, Jane Street Group LLC increased its holdings in shares of Protalix BioTherapeutics by 159.0% in the 1st quarter. Jane Street Group LLC now owns 294,318 shares of the company’s stock valued at $753,000 after purchasing an additional 180,702 shares in the last quarter. Institutional investors and hedge funds own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics (NYSE:PLX) is a clinical?stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost?effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high?quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.